HUM-MOLGEN events: GENE QUANTIFICATION

HUM-MOLGEN -> Events -> Meetings and Conferences

December 05, 2000

Cambridge Healthtech Institute, San Diego, California
February 12-13, 2001

The quantification of genes has grown to the stature of a mature science. We stand on the threshold between relative and absolute quantification. This will cause a ripple effect throughout the entire process—from the concomitant need for more precise sample preparation to a more complete understanding of what it is that these absolute numbers mean in the biological sense. For example, does it mean anything when we say, "Beta Actin is highly conserved," if we fail to ascribe numbers to other parameters? And can we get around sample contamination measurement interfering with sensitivity by simply setting a cutoff point before the negative controls are tripped?

Organized by:

Cambridge Healthtech Institute

Invited Speakers:

Dr. Xian Chen, Los Alamos National Laboratory
Dr. Steven Daniel, Genometrix Inc.
Dr. Soren Germer, Roche Molecular Systems, Inc.
Dr. Andrew Goldsborough, Cyclops Genome Sciences Ltd.
Dr. David Hendricks, Bayer Diagnostics, Inc.
Dr. David J. Ingham, Novartis Agribusiness Biotechnology Research, Inc.
Dr. John Irving, Geron Corporation
Dr. James W. Jacobson, Luminex Corporation
Dr. Robert Kwiatkowski, Third Wave Technologies, Inc.
Dr. William B. Mattes, Pharmacia Corporation
Dr. Andrew Medhurst, SmithKline Beecham
Dr. George Orphanides, AstraZeneca, Inc.
Dr. Jinmei Pan, Wyeth-Ayerst Research
Dr. Sanjay Tyagi, Public Health Research Institute of New York
Dr. Susan Wharam, Cytocell Ltd.
Dr. James C. Willey, Gene Express National Enterprises, Inc.
Dr. Xiao Xu, Nanogen, Inc.
Mr. Lawrence Yoon, GlaxoWellcome

Deadline for Abstracts:

January 5, 2001

Registration:

Available on-line

E-mail:

jlaakso@healthtech.com

Posted by:

Jennifer Laakso

Host:

wks217.healthtech.com